# Trinity Capital Inc.: financial statements, quarterly

TRIN · NYSE · CIK 1786108 · [Other](/sectors/other.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/trin.md) · [Financials](/companies/trin/financials.md) · [Filings](/companies/trin/filings.md) · [Insiders](/companies/trin/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/trin/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net income | $m | [16.8](/filings/0000950170-24-118600.md) | [17.7 d](/filings/0001193125-26-068600.md) | [14.5](/filings/0000950170-25-065028.md) | [30.8](/filings/0000950170-25-103547.md) | [24.4](/filings/0001193125-25-265807.md) | [45.9 d](/filings/0001193125-26-068600.md) | [27.1](/filings/0001193125-26-207620.md) | [41.4](/filings/0001193125-26-333907.md) | [27.6](/filings/0001193125-25-265807.md) | [39.5 d](/filings/0001193125-26-068600.md) | [29.8](/filings/0001193125-26-207620.md) | [44.4](/filings/0001193125-26-333907.md) |
| Diluted EPS | $ per share | [0.40](/filings/0000950170-24-118600.md) | not reported | [0.30](/filings/0000950170-25-065028.md) | [0.59](/filings/0000950170-25-103547.md) | [0.43](/filings/0001193125-25-265807.md) | not reported | [0.43](/filings/0001193125-26-207620.md) | [0.63](/filings/0001193125-26-333907.md) | [0.39](/filings/0001193125-25-265807.md) | not reported | [0.36](/filings/0001193125-26-207620.md) | [0.49](/filings/0001193125-26-333907.md) |
| Basic EPS | $ per share | [0.42](/filings/0000950170-24-118600.md) | not reported | [0.31](/filings/0000950170-25-065028.md) | [0.61](/filings/0000950170-25-103547.md) | [0.45](/filings/0001193125-25-265807.md) | not reported | [0.43](/filings/0001193125-26-207620.md) | [0.63](/filings/0001193125-26-333907.md) | [0.39](/filings/0001193125-25-265807.md) | not reported | [0.36](/filings/0001193125-26-207620.md) | [0.49](/filings/0001193125-26-333907.md) |

- Net income: us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [7.2](/filings/0000950170-23-057140.md) | [4.8](/filings/0001193125-26-068600.md) | [12.0](/filings/0000950170-24-050904.md) | [46.1](/filings/0000950170-24-092284.md) | [8.5](/filings/0000950170-24-118600.md) | [9.6](/filings/0001193125-26-068600.md) | [8.4](/filings/0000950170-25-065028.md) | [26.3](/filings/0000950170-25-103547.md) | [9.5](/filings/0001193125-25-265807.md) | [19.1](/filings/0001193125-26-333907.md) | [19.6](/filings/0001193125-26-207620.md) | [22.2](/filings/0001193125-26-333907.md) |
| Total assets | $m | [1,151](/filings/0000950170-23-057140.md) | [1,311](/filings/0000950170-25-027341.md) | [1,410](/filings/0000950170-24-050904.md) | [1,505](/filings/0000950170-24-092284.md) | [1,735](/filings/0000950170-24-118600.md) | [1,774](/filings/0001193125-26-068600.md) | [1,857](/filings/0000950170-25-065028.md) | [2,045](/filings/0000950170-25-103547.md) | [2,247](/filings/0001193125-25-265807.md) | [2,485](/filings/0001193125-26-333907.md) | [2,556](/filings/0001193125-26-207620.md) | [2,805](/filings/0001193125-26-333907.md) |
| Total liabilities | $m | [581](/filings/0000950170-23-057140.md) | [700](/filings/0000950170-25-027341.md) | [783](/filings/0000950170-24-050904.md) | [825](/filings/0000950170-24-092284.md) | [978](/filings/0000950170-24-118600.md) | [951](/filings/0001193125-26-068600.md) | [1,024](/filings/0000950170-25-065028.md) | [1,121](/filings/0000950170-25-103547.md) | [1,249](/filings/0001193125-25-265807.md) | [1,391](/filings/0001193125-26-333907.md) | [1,390](/filings/0001193125-26-207620.md) | [1,539](/filings/0001193125-26-333907.md) |
| Long-term debt | $m | [533](/filings/0000950170-24-118600.md) | [646](/filings/0001193125-26-068600.md) | [738](/filings/0000950170-25-065028.md) | [772](/filings/0000950170-25-103547.md) | [923](/filings/0001193125-25-265807.md) | [888](/filings/0001193125-26-068600.md) | [968](/filings/0001193125-26-207620.md) | [1,061](/filings/0001193125-26-333907.md) | [1,186](/filings/0001193125-25-265807.md) | [1,306](/filings/0001193125-26-068600.md) | [1,359](/filings/0001193125-26-207620.md) | [1,514](/filings/0001193125-26-333907.md) |
| Shareholders' equity | $m | [569](/filings/0000950170-23-057140.md) | [611](/filings/0000950170-25-027341.md) | [626](/filings/0000950170-24-050904.md) | [680](/filings/0000950170-24-092284.md) | [757](/filings/0000950170-24-118600.md) | [823](/filings/0001193125-26-068600.md) | [833](/filings/0000950170-25-065028.md) | [924](/filings/0001193125-26-333907.md) | [998](/filings/0001193125-25-265807.md) | [1,094](/filings/0001193125-26-333907.md) | [1,166](/filings/0001193125-26-207620.md) | [1,267](/filings/0001193125-26-333907.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [55.5 d](/filings/0000950170-24-118600.md) | [(136) d](/filings/0001193125-26-068600.md) | [(81.4)](/filings/0000950170-25-065028.md) | [(21.9) d](/filings/0000950170-25-103547.md) | [(232) d](/filings/0001193125-25-265807.md) | [18.4 d](/filings/0001193125-26-068600.md) | [(63.3)](/filings/0001193125-26-207620.md) | [(124) d](/filings/0001193125-26-333907.md) | [(184) d](/filings/0001193125-25-265807.md) | [(165) d](/filings/0001193125-26-068600.md) | [(45.8)](/filings/0001193125-26-207620.md) | [(199) d](/filings/0001193125-26-333907.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [36.5](/filings/0000950170-23-057140.md) | [38.7](/filings/0000950170-24-050904.md) | [39.7](/filings/0000950170-24-092284.md) | [43.9](/filings/0000950170-24-118600.md) | [50.6](/filings/0000950170-25-065028.md) | [54.1](/filings/0000950170-25-103547.md) | [58.4](/filings/0001193125-25-265807.md) | [62.6](/filings/0001193125-26-207620.md) | [65.9](/filings/0001193125-26-333907.md) | [71.5](/filings/0001193125-25-265807.md) | [83.6](/filings/0001193125-26-207620.md) | [90.5](/filings/0001193125-26-333907.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 94,693,574 at 2026-08-03, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-333907.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.